STERIS forward PE STE
Share price divided by analysts' consensus earnings for the next twelve months, since 1996.
- Today, Oct 23, 2026
- 20.2×
- 10-year median
- 24.3×
- Against its 10-year history
- 11th
- percentile: 0 is its lowest day, 100 its highest
- 10-year range
- 17.2× to 31.6×
- Peer median
- 24.9×
STERIS' forward PE is 20.2× as of Oct 23, 2026.
That is below its ten-year median of 24.3×, lower than on 89% of days in the last ten years.
Over that time it ranged from 17.2× in Dec 2016 to 31.6× in Feb 2020.
The median for 10 healthcare stocks of a similar size is 24.9×.
Forward PE over time
The dashed line is the 10-year median and the shaded band the middle half of its days.
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 20.2× | 17.9× | 25.4× |
| 2025 | 24.2× | 21.4× | 25.2× |
| 2024 | 21.8× | 21.8× | 26.9× |
| 2023 | 25.5× | 21.6× | 27.7× |
| 2022 | 22.5× | 19.9× | 30.7× |
| 2021 | 30.9× | 24.8× | 30.9× |
| 2020 | 28.7× | 21.7× | 31.6× |
| 2019 | 29.0× | 20.7× | 29.6× |
| 2018 | 20.9× | 19.9× | 24.7× |
| 2017 | 20.4× | 17.8× | 22.4× |
| 2016 | 17.8× | 16.2× | 19.5× |
| 2015 | 20.1× | 18.0× | 24.3× |
| 2014 | 24.2× | 16.0× | 24.2× |
| 2013 | 17.8× | 14.4× | 17.8× |
| 2012 | 14.1× | 13.0× | 15.5× |
| 2011 | 13.7× | 12.7× | 16.1× |
| 2010 | 16.0× | 13.3× | 17.2× |
| 2009 | 15.7× | 15.4× | 22.8× |
| 2008 | 19.1× | 19.1× | 43.6× |
| 2007 | 24.7× | 19.9× | 25.0× |
Against its peers
Companies in Healthcare nearest STERIS' size, closest first, today.
| Company | Forward PE |
|---|---|
| STESTERIS | 20.2× |
| INCYIncyte | 49.5× |
| THCTenet Healthcare | 12.9× |
| UTHRUnited Therapeutics | 22.0× |
| LHLabcorp | 17.4× |
| DGXQuest Diagnostics | n/m |
| ZBHZimmer Biomet | n/m |
| MEDPMedpace | n/m |
| WSTWest Pharmaceutical Services | 42.2× |
| RVTYRevvity | n/m |
| DXCMDexCom | 27.7× |
| Peer median | 24.9× |
Where STERIS ranks
What the forward PE tells you
Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.
Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.
More on STERIS
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.